Growth Metrics

ADC Therapeutics (ADCT) Equity Income (2023 - 2024)

ADC Therapeutics has reported Equity Income over the past 2 years, most recently at -$260000.0 for Q3 2024.

  • Quarterly results put Equity Income at -$260000.0 for Q3 2024, up 81.55% from a year ago — trailing twelve months through Sep 2025 was -$260000.0 (up 93.45% YoY), and the annual figure for FY2023 was -$6.0 million, changed.
  • Equity Income reached -$260000.0 in Q3 2024 per ADCT's latest filing, up from -$597000.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$260000.0 in Q3 2024 and bottomed at -$2.4 million in Q4 2023.